Loading…
USApeptide.com was cited for unlawfully selling unapproved and misbranded drugs—specifically semaglutide and tirzepatide—to U.S. consumers via the internet in violation of the Federal Food, Drug, and Cosmetic Act. Despite labeling claims of "research use only" and "not for human consumption," the FDA determined the products were marketed with evidence of intended human use, including references to FDA-approved brand names like Ozempic and Wegovy and weight-loss benefits. The agency found that these unapproved drugs circumvented regulatory safeguards and posed inherent risks to consumers due to potential contamination, counterfeiting, varying ingredient amounts, or undisclosed ingredients. The FDA requested immediate cessation of sales of all unapproved and misbranded drugs to protect public health.